The combination of multiple CRISPR-Cas9 editing of TRAC, TCRβ constant, and PDCD1 with introduction of a cancer-specific TCR transgene (NY-ESO-1) improved anti-tumor immune responses and reduced TCR mismatches in a phase I human clinical trial (Stadtmauer et al., 2020). Here, TRAC is linked to neoplasm.